Does cell therapy and tissue engineering represent a promising ....pdf

Loading ...
Global Do...
News & Politics
Bratisl Lek Listy 2010; 111 (3)
  
Indexed and abstracted in Science Citation Index Expanded and in Journal Citation Reports/Science Edition
	




 !
"#$
%$&'(
#)$**$+
#$"%$)%$,%'
	
	#-"$	.
$
$#
)$**$+#$
"%$,'%/$,0123342)%$,%'-
	
5'5 *"06
//768447$
*36497:642#;,%'	1
 &.-844:69<1"014:-
	

		



	

	
			
Abstract: Diabetes mellitus is one of the most severe and costly chronic disease of our time. Approximately
2–3 % of diabetics have an active foot ulcer, and 15 % of all patients with diabetes will develop an ulcer during
their lifetime. Treatment of foot complications is one of the main items in the absorption of enormous economic
and health resources addressed to the diabetic patients. Advances in basic science, tissue culture techniques
and cell therapy promise to improve the treatment of diabetes as well as its complications, i.e. also the ischemic
ulcers of the foot. At present, the isolation of any specific type of cells, their in vitro expansion and biological
characterization of acquired cell population are possible. For the healing process in ischemic diabetic ulcers,
stem cells, endothelial progenitor cells and fibroblasts, both in suspension or placed on an extracellular scaf-
fold are used. This process is focused on stimulating the new blood vessels formation. This is stimulated by
the paracrine secretion of multiple growth factors and their receptors. Verified are the vascular endothelial
growth factor and its receptor, fibroblast growth factor, interleukin-8 and proangiogenic cytokines (Ref. 62).
Full Text (Free, PDF) www.bmj.sk.
Key words: diabetic foot ulcer, cell therapy, tissue engineering, clinical trials.
 
& 831
-$   1
&3:38444=%8-2>?
9<<8494=%/-/>?=3?-
   $
-
5  
%  53>/-3>$
4-83@3-9:>=8?-
 1
1 5
' AB1
97<7>=9$/?-
A5
'C=D2
5'?$$=B?-%
5 %1
=<$:?$5 1
=2$7?-
  
$    &%%
%E=34?-	' 1
   $ $ $
'=33?-
 
 &   %%3B> 844
5 55-1
     $  $ 
=<?-1
FB4>5%
&3-#A& -1
3$8B>$893-<>9
<4>-5%
$B@34>5 511'
3B@84>5 %11'=33?-#
<4>1  55
 -#&
 EC
-% 
&=38?-
, 
 $ 1$ $   $
%G-

		
 1
  5  -#    A
5 
%HI$ G
5$%1&$
    =39?-
 %%$

Ulicna M et al. Does cell therapy and tissue engineering represent…
%$1
%F& 
F 
5-
   5  % 1
5I%
=
?5 '%
%&'=3/?-
 $$=1
$% $1
    ?  I  =5 $
$I%?
5-5'5%1
=?$51
 $A& -
 84> 5I%5
$B4>5%
 $94>5% =3B?-
$
 1
 5-
	 !		

$%1
 5 
5 % -.=?%1
  5$  % =3<?-
51I1
   %      
A1'=3:$32?-		1
-
+$  $ 
=II
?-
"
+      C  %  
'-+  
5%  
5&-  
5 $I1
 =37?-
     G   
'$'-;5%$1
 '
5-+  
%%
*+1β3 A%*+1β31
-$
*+$+*+18$
*+*+1β %
555=84$83?-
%
5A%
    $ '    =88?-
;5%$  5  %
 I   ' 5 

#5$ '1
=89?-
%5%1
 $-'1
$ $α
8
 $ 
 5$'% 
5=8/?-%5
5  1
%$$$1
%5=8B?-
  $5% 
5
% $1
 G $  6'1
-
#!$%

=%,6,J.5?
A1 -;5 1
       $ 1
 $'61
55-

$  1I1
I 
-;$1
 5 
-&
 :4>34>55$
 1
-  %&I
I $1
-+55
1    
5 5%  %5
' 1
$1
=8<$8:?-
&
!
'$
($)*
*'=F$$#$.%1
$
;%$.(? 11
'C%  %   
"-,- %=82$87?- 
 A %1
C$%1
'-%% '
  I5A %
AI- ''I
35'-  
'
'-HI1
I$ %      $ 
'-II1
A %G  1
 1=94?-"''$*'

Bratisl Lek Listy 2010; 111 (3)
 
      %$  $ 
5$1
$=87?-;,
+
1%
 %$ 
 1
-;,
1
5I3B5
6''55-)
G 1;,
 
51
 %
%5=93?-
+	&

  G% $%
%*'$$
 -8/
"-,-$84251
5*'1G=
?-3815'51%$B<>*'1
%5592>
-*'A
55111%1
      5   
=98?-

-
*'5 385'=99?-
)	
, =,?G
% % $1
=9/@9<?-,%151
$51	1
-, 1
  5$ $
$    $ $ % $
$$$$  $$
=9:?-
,	
)55  
  - )5   
=#,?$5%
 =?     $  
$$ $
 $    ' =92?-#, 
 $ 	=97?	=/4?-
0-#,
 ' 
 %
=/3?-%5=
*+?$
  5=+*+?$13=13?$I
 =##?   5  K
=*+1K?-  5   $   

 #,1=/3?-
*
	*+

 %1
%G 1
5=3/$/8?-

$5%$$
 %
C     -

 =;,?%
 = ?  
'11
13=
#136
93?$%5
8=
*+	8$'50
	+'3?$%1
 =%+?$%=
1?$
18$10$,13$399$
9/=/9@/2?-$

 'I
-
A
I%1
  
=/<?-"% 
$
-,1

A'
=/7?-&%1
- 
 8B>
5%
=B4?-,$ % 1
 )#1%
     
%5$ =B3?$
=B8?$%
=B9?$=B/?$%1
=BB?$%5=B<?$
5=B:?-
+	
%'1
 
399L=B2?-1
    1%
399L   
5  5  =B7?-
5%58I34/
399L
-I%=?
$5 5151

3991511
-
399L51
%1
$$%% 1
-
399L%%1
5=
*+?1'=?12- 
%-
*%1
 5 5 

Ulicna M et al. Does cell therapy and tissue engineering represent…
5 - 1
&%I=%
 ? &%I'
 I=)?$I=
8
?$
$$%15
5%- 
5 
%5 =<4?-
$MG'9:5
%
 =--%G%
?5 
5=)#,?-5
 %%1
$5-
 I$%1
5-
  $'1
$)$ $

8
55
8
%-1
&A%%%
)#,=<3?-
    )#,   
         
 =?A 51
=#,?%E 1
55C1
5= ?=<8?-E 5
55&
5%51
 -I 5#,
5:3:-87 
$55%5G$
%'
5 -
+	

5$1
    %
%-  C$1
% %G1
5 -
%%5%
5-% '
5  '
   %      -
-	
./)0-	&0&0)	-01$* %
 H8444&8494-
 
844/F8:H34/:N34B9-
2,+304#5-	
 -
 	844/F/H/39N/32-
6-&*0,
*50)#&5I
 -
 -*%1
377B
74#04	
-0)
#-
 51 
HA%-
 
3772
F
83H:92-
8/	
,5-
(.377<F89H829N874-
93+
 NA%%5-,1
844:FB=/?H837N893-
:;404	)3-' -
3773F7HBBBNB<9-
<)
,*03;0,- %  
 -#,8449F84H
<27N:42-
=/)+0#>-0/5)0#&-+
  H %  -;	'#
844:F9H<BN:<-
.?#50--,#
=
?-,*-(,8444F93H3N87<-
..)	-40@54- H%
!#3777F394H//8N///-
.2# 30 "*     H 
%%5-
 	%844<F=/?H
/93N//:-
.64;0AB)101A51
HA-
	,844<F33:=,?H9BN/3-
.73C50> ( A+;I$ 
 
# G$ 
 ;-I	I ,
8442F34=33?H32<7N3228-
.8-&*0>
30,
*5040)#&0
330,5551I1
5 5-
 3777F
88H3B:N3<8-
.9$3*0*4+H
*+
%$ $   - )

	
 8449F<7H9<9N9:/-
.:#D>0,A0,$ 1
%-	8449F93/H34:N33:-
.<)--	844/F
33:H9N98-
.=& 50+
-"- ,  %     O  K3
           %
I $% -(%
1
377<F34<H348N342-
2?$04$$"
  
%%  *+1K3- (
,377:F3<HB7N<<-
2.+
#40E*C0$
1
'5-,37//F837H<22N<78-
22#	
/+0"	50-)1%
5-(
# 844/F27H2/:N2B3-

Bratisl Lek Listy 2010; 111 (3)
 
26/)50)
4503
%I1
1819   -)(

8449F3/7H39N3<-
27">0*/$-%1
-3779F93/H344<N3442-
28)5;0">-%%5-(1
#,8449F:H3837N88/-
29450310-*0	-0-	0%
&1*5   H1
 -
  # 3777FBH8<BN:7-
2:4;0$505/&0$1
1
%I%-
		8449F33=/?H878N87<-
2<,*0*	$0,#50
D;%
%'1C%'-,1
3723F833H34B8N34B/-
2=*/$0@403 1HA' 
=*'?5HI-
,
377BF83H297N2/9-
6?#;30>-        
 -	,844<F33:=:?H3B8N3B:-
6.,$0E50;	%+	40@	+0*	$1
 %'C%
=;,
? -,8449F33H
89N93-
62>0">0#&0)
43-*'$
; ,' 
C%$  
%   #  .1
 . 
  + "- 
   8443F 8/H
874N87B-
66*4

 +"1
,*- 
-(5
I8447F2=3?H33N32-
67;50@
 %*50)
))0/
 40)%
5504>)0554
   %
 -,3772F828H33/BN33/:-
681/0,04/0+5/0
$-
)	844BF:8H3484N3482-
69,
#0)30;-)H1
G$$-(
##844/F2H943N93<-
6:+"$0;-)#-
	8442F34H889-
6<E	E0E)0)
E01;0$D10
A 10$>50E
10$)	1
  5I 5%1
I 5-
)(
844/F3B3=B?H3437N3482-
6=%10*
04#03D303	
%
10&
5 5

*+1%%-*8449F34H
<83N<87-
7?&-01,0$ 0>F%1 403
G0"	4,0/ 
&)5%
%% 1
-
844BF33H27<N749-
7.1;0)*0,4)03+/0,)0"	)0
*
)*#51%   I   
 ' % 
%%-	844/F
7/H<:2N<2B-
72;04$0;
;01
+0+0)
40140440@54)51
 %1
   %G-	 3777F 2BH
883N882-
76"@0-/-%1
%-
%3778F33<H/9BN/97-
77$/  5 - 0,
*#3744F88H3:3N982-
78/450A
)$% 
-.5  - ( %377<F7:H
B73NB7B-
7910;	

%
"-G1
%%844:F:4H/::N/2/-
7:&+0#D*;H
'- )377:F3:H3379N3848-
7<$40*/0/+
H 1
G$ $  - )
8449F89H332BN3327-
7=,)40,-50> ( A+$1
$5-
%,
844BF97=/?H879N94B-
8?;

A40&-#0+
5401
+0&505	%
 &-0350&&+; 
      I   $ $
   % -  8448F 34<H
8:23N8:2<-
8.1
+04$0;
;01
%4/40)40
1403;0@540;I%%
I      %G1
-.,",8444F7:H9/88N9/8:-
82A	#01D50+)0,#4030
 5  
-.P,8443F792H883N887-
861)0&*0&150)
A40;0
)"/0-
*0440)	"500)
)0,	5045*5+1%1
II%%-.#8443F
:H 349BN34/4-
87)40)010;D0A
)0;
;0
$$04
	40$E0--;
 %   
-.#8448F2H/49N/47-
88&4,04/)0+)0,&0& )40
4-0,,50>;0)
*0	
,0)	*/
% 1
%%G-.#8448F2H<4:N<38-

Ulicna M et al. Does cell therapy and tissue engineering represent…
89E0$0)4)
*+
 51%=
?%1
 5  -.,",8448F
77H 337B3N337B<-
8:3#0$10#)0++0,
0,30+%
0$,04
/0/30/E0$	
#0CC0
$	
-0+-&0440$DD10410,%
 -0-) 151%1
  '  
5-.#8443F:H337/N3843-
8<E$04)0CD*#0%&0A
403&0A 501 50,	
#/399$ .%
#' ;; , -)
377:F74=38?HB448NB438-
8=,	3)0#
+01H
0&&0@	&01%
-0)40440+
@04	40)0+%

04&0)30&0*+0
4;
399L;

 " ,
%,-	8447F3B8/N/B:3-
9?&E0C50I3%1
 5 5 
   5   -QR+ (
0QQ844:F83=:?H<:BN<:2-
9.	J 
>0&	50+J50101&30
5 ;0+ K#01D	5 5
51 1
 -'8447FBB=9?H3:9N3:2-
92>DLLJ
50#LM301L40,
L#05J
30GMJ
40,L
4 1
 -.
844<F8:=,8?H
39/N39:-
	%#94$8447-
(B$8434-